Clinical Trials Browser

OTHER × Interventional × brigatinib × Clear all

NCT04318938 2026-03-02

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Phase 2 Active not recruiting

NSCLC

NCT04223596 2026-02-04

CUBIK

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04374305 2026-01-12

INTUITT-NF2

Phase 2 Active not recruiting

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT04925609 2025-12-05

Briga-PED

Phase 1/2 Recruiting

LymphoidPlasma cell

Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT05200481 2025-11-17

MP-ALK

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03707938 2025-11-03

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04227028 2025-09-16

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06522360 2025-04-24

Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT06813079 2025-02-18

Using Tumor Models to Determine Treatments

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Carcinoma, Pancreatic Ductal

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT04634110 2022-10-24

Brigatinib Before Brain Irradiation Trial (B3i Trial)

Phase 2 Terminated

1 enrolled 6 charts

Brain Neoplasms, Lung Neoplasms

NCT04005144 2022-10-17

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Disease Progression

NCT05361564 2022-05-04

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03868423 2022-02-18

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Phase 2 Withdrawn

Brain Neoplasms, Neoplasm Metastasis

NCT03719898 2021-01-05

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Phase 2 Withdrawn

Lymphoma, Large-Cell, Anaplastic